(Q53576678)

15 May 2018

title

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. (English)

1 reference

15 May 2018

1 reference

9

1 reference

15 May 2018

author name string

Jose A Karam

1

1 reference

15 May 2018

Jinhai Fan

2

1 reference

15 May 2018

Jennifer Stanfield

3

1 reference

15 May 2018

Edmond Richer

4

1 reference

15 May 2018

Elie A Benaim

5

1 reference

15 May 2018

Eugene Frenkel

6

1 reference

15 May 2018

Peter Antich

7

1 reference

15 May 2018

Arthur I Sagalowsky

8

1 reference

15 May 2018

Jer-Tsong Hsieh

10

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 April 2007

1 reference

15 May 2018

International Journal of Cancer

published in

1 reference

15 May 2018

volume

120

1 reference

15 May 2018

issue

8

1 reference

15 May 2018

page(s)

1795-1802

1 reference

15 May 2018

cites work

Cancer statistics, 2005

1 reference

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes

21 January 2018

1 reference

Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening

21 January 2018

1 reference

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription

21 January 2018

1 reference

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer

21 January 2018

1 reference

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells

21 January 2018

1 reference

Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells

21 January 2018

1 reference

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

21 January 2018

1 reference

An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies

21 January 2018

1 reference

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

21 January 2018

1 reference

Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome

21 January 2018

1 reference

Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease

21 January 2018

1 reference

DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci

21 January 2018

1 reference

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

21 January 2018

1 reference

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

21 January 2018

1 reference

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells.

21 January 2018

1 reference

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

21 January 2018

1 reference

Novel form of p21(WAF1/CIP1/SDI1) protein in phorbol ester-induced G2/M arrest

21 January 2018

1 reference

Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication

21 January 2018

1 reference

Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.

21 January 2018

1 reference

Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).

21 January 2018

1 reference

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy

21 January 2018

1 reference

Validating Bioluminescence Imaging as a High-Throughput, Quantitative Modality for Assessing Tumor Burden

21 January 2018

1 reference

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.301

Identifiers

DOI

10.1002/IJC.22405

1 reference

15 May 2018

PubMed ID

17230511

1 reference

15 May 2018